For a small company seeking to market a rival to a dominant brand, a patent lawsuit from a global pharma giant would seem to be a cause for concern. But Revance has a good chance of beating back AbbVie’s recent patent case, one team of analysts figures.
After AbbVie earlier this month filed an infringement suit against Revance on five Botox patents, analysts with Wells Fargo spoke with a patent expert who believes the suit is “very unlikely to derail” Revance’s potential launch of daxibotulinumtoxinA.
AbbVie’s Botox Patent Lawsuit is ‘Very Unlikely to Derail’ Revance’s Rival Launch: Analysts
